Efficacy, Durability, And Retreatment Outcomes Of Risankizumab In Moderate To Severe Plaque Psoriasis: Results From The Phase 3 Immhance Trial. (2016). Journal of Carcinogenesis, 15(1). https://doi.org/10.64149/